"Interleukin-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
Descriptor ID |
D007376
|
MeSH Number(s) |
D12.644.276.374.465.021 D12.644.276.374.480.372 D12.776.467.374.465.021 D12.776.467.374.480.372 D23.529.374.465.155 D23.529.374.480.372
|
Concept/Terms |
Interleukin-2- Interleukin-2
- Interleukin 2
- IL-2
- IL2
- TCGF
- Interleukine 2
- Lymphocyte Mitogenic Factor
- Mitogenic Factor, Lymphocyte
- T-Cell Growth Factor
- T Cell Growth Factor
- T-Cell Stimulating Factor
- T Cell Stimulating Factor
- Thymocyte Stimulating Factor
- Interleukin II
Ro-23-6019- Ro-23-6019
- Ro 23 6019
- Ro236019
- Ro-236019
- Ro 236019
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-2".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-2".
This graph shows the total number of publications written about "Interleukin-2" by people in this website by year, and whether "Interleukin-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 9 | 5 | 14 |
1995 | 15 | 9 | 24 |
1996 | 8 | 9 | 17 |
1997 | 10 | 6 | 16 |
1998 | 8 | 5 | 13 |
1999 | 3 | 8 | 11 |
2000 | 8 | 9 | 17 |
2001 | 8 | 4 | 12 |
2002 | 7 | 9 | 16 |
2003 | 7 | 11 | 18 |
2004 | 5 | 8 | 13 |
2005 | 8 | 4 | 12 |
2006 | 6 | 7 | 13 |
2007 | 7 | 9 | 16 |
2008 | 11 | 15 | 26 |
2009 | 6 | 11 | 17 |
2010 | 4 | 10 | 14 |
2011 | 6 | 9 | 15 |
2012 | 9 | 7 | 16 |
2013 | 3 | 5 | 8 |
2014 | 5 | 7 | 12 |
2015 | 2 | 4 | 6 |
2016 | 7 | 1 | 8 |
2017 | 2 | 7 | 9 |
2018 | 3 | 2 | 5 |
2019 | 3 | 2 | 5 |
2020 | 6 | 2 | 8 |
2021 | 2 | 1 | 3 |
2022 | 6 | 7 | 13 |
2023 | 0 | 1 | 1 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-2" by people in Profiles.
-
A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting Aspergillus fumigatus. mBio. 2024 Apr 10; 15(4):e0341323.
-
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2).
-
Conditional deletion of CD25 in the corneal epithelium reveals sex differences in barrier disruption. Ocul Surf. 2023 Oct; 30:57-72.
-
Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors. Clin Cancer Res. 2022 Dec 01; 28(23):5121-5135.
-
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature. 2022 10; 610(7930):173-181.
-
Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation. Front Immunol. 2022; 13:891925.
-
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nat Commun. 2022 06 16; 13(1):3477.
-
Cohort study on the differential expression of inflammatory and angiogenic factors in thrombi, cerebral and peripheral plasma following acute large vessel occlusion stroke. J Cereb Blood Flow Metab. 2022 10; 42(10):1827-1839.
-
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. Eur Urol. 2022 10; 82(4):365-373.
-
The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response. Genes Dev. 2022 05 01; 36(9-10):582-600.